SciELO - Scientific Electronic Library Online

vol.12 número2Contaminación Enterobacteriana del Guarapo de una Fábrica de Cochabamba, en Fermentación Normal y Fermentación FlemosaConsumo de Alcohol durante el Embarazo: Múltiples Efectos Negativos en el Feto índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • No hay articulos similaresSimilares en SciELO


Revista Científica Ciencia Médica

versión impresa ISSN 1817-7433versión On-line ISSN 2220-2234


CRESPO HERRERA, Sonia. Metformin, 50 years of use: Effectiveness, tolerance, security and new indications. Rev Cient Cienc Méd [online]. 2009, vol.12, n.2, pp.23-25. ISSN 1817-7433.

Metformin began to be used in the treatment of type 2 diabetes mellitus in 1957 in Europe and 1995 in EE. UU. He is currently the most frequently prescribed oral anti-hyperglycaemic worldwide. In 1998, the United Kingdom Prospective Diabetes Study demonstrated antiatherogenic effects of metformin and later discovered that improved many components of insulin resistance syndrome (metabolic syndrome). The U.S. Diabetes Prevention Program demonstrated the potential of metformin in preventing diabetes. Its efficacy, safety, multiple cardiovascular and metabolic benefits, and the ability to be used in combination with all other antidiabetic agents, including insulin, metformin has made in the first line oral drug for the treatment of patients with diabetes mellitus type 2. In recent years evidence has surfaced to indicate metformin in nondiabetic patients, primarily those with metabolic syndrome, glucose intolerant and women seeking a pregnancy and suffer from polycystic ovary syndrome. It could also improve the clinical characteristics of insulin resistant states, apart from type 2 diabetes. Its role in cancer prevention could be another of the developments of metformin in the future. The objective of this review is to update on the new guidelines of the drug.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons